Data Supports Abbott Tendyne Mitral Valve Replacement
Abbott reported new study findings supporting the use of its Tendyne transcatheter mitral valve replacement (TMVR) system.
Tendyne offers an option for patients with mitral valves that fail to function properly due to severe mitral annular calcification (MAC), which stiffens the annulus ring-like structure that supports the mitral valve, leading to mitral regurgitation or stenosis.
For patients with severe MAC at high risk for open-heart surgery, who cannot have their valve repaired with Abbott’s MitraClip, Tendyne delivers a minimally invasive alternative to replace the leaky or narrowed valve.
Tendyne, which! uses nitinol, received FDA approval in May, and Abbott reported the first commercial implant last month.
Abbott (NYSE: ABT) supports the use of its Tendyne transcatheter mitral valve replacement (TMVR) system.
Author summary: Abbott's Tendyne supports mitral valve replacement.